Physician profile
David Ys Lee
NPI 1861505703
$21,771.37
in general payments reported to CMS, 2019-2025
70 companies · $2,629 in 2025
The $2,629 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,020 · 2020: $1,394 · 2021: $3,264 · 2022: $3,516 · 2023: $3,233 · 2024: $3,716 · 2025: $2,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,480 · Education: $97.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,480.37 |
| Education | $97.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,568.90 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $2,019.91 | 2019-2025 | |
| Eisai INC. | $1,150.60 | 2019-2025 | |
| Biogen, INC. | $1,085.52 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $1,072.16 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Emd Serono, INC. | $981.34 | 2019-2024 | Mavenclad |
| Genentech USA, INC. | $947.43 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Amgen INC. | $801.11 | 2019-2025 | Uplizna, Aimovig |
| Janssen Pharmaceuticals, INC | $656.87 | 2021-2025 | Spravato |
| Sunovion Pharmaceuticals INC. | $591.88 | 2019-2022 | |
| Celgene Corporation | $581.28 | 2021-2025 | Zeposia |
| Lilly USA, LLC | $502.32 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Jazz Pharmaceuticals INC. | $469.80 | 2019-2023 | Epidiolex |
| Supernus Pharmaceuticals, INC. | $427.43 | 2019-2024 | Qelbree |
| Alexion Pharmaceuticals, INC. | $427.16 | 2019-2023 | Ultomiris |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.